Literature DB >> 26884882

Genetic polymorphisms of C-reactive protein increase susceptibility to HBV-related hepatocellular carcinoma in a Guangxi male population.

Xianjun Lao1, Shan Ren1, Yu Lu1, Dongmei Yang1, Xue Qin1, Shan Li1.   

Abstract

C-reactive protein (CRP) is a biomarker of inflammation and the production has been shown to be influenced by genetic variation in CRP gene. HBV-related hepatocellular carcinoma (HCC) is a typical inflammation-related disease occurs mainly in men. The present study was designed to investigate the association between CRP polymorphisms and HBV-related HCC risk in a Chinese male population. The CRP rs2794521 and rs3093059 SNPs were genotyped by polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP) in 158 HBV patients with HCC, 207 HBV patients without HCC, and 150 unrelated healthy controls. A significant increased HCC risk in HBV patients were observed for the rs3093059 SNP comparing with those without HCC (C allele vs. T allele: adjusted OR=1.56, 95% CI, 1.07-2.29, P=0.021; TC vs. TT: adjusted OR=1.77, 95% CI, 1.13-2.76, P=0.012; TC/CC vs. TT: adjusted OR=1.76, 95% CI, 1.14-2.71, P=0.011). However, we did not observe any significant association of rs3093059 polymorphism with HCC when compared with healthy controls. With respect to rs2794521 polymorphism, no significant associations of this polymorphism with HCC risk were found in this population. In haplotype analysis between HBV patients with HCC and HBV patients without HCC, the TC haplotype was found correlated with a significant increased HCC risk (OR=1.803, 95% CI, 1.237-2.335, P<0.001). We concluded that the CRP rs3093059 polymorphism may play a significant role in the development of HBV-related HCC in the Guangxi male population.

Entities:  

Keywords:  C-reactive protein; Hepatocellular carcinoma; chronic hepatitis B; male; polymorphism

Mesh:

Substances:

Year:  2015        PMID: 26884882      PMCID: PMC4730095     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  30 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression.

Authors:  Yong-Cang Wang; Ge-Liang Xu; Wei-Dong Jia; Sheng-Jin Han; Wei-Hua Ren; Wei Wang; Wen-Bin Liu; Chuan-Hai Zhang; Hao Chen
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

3.  Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma.

Authors:  Wolfgang Sieghart; Matthias Pinter; Florian Hucke; Ivo Graziadei; Maximilian Schöniger-Hekele; Christian Müller; Wolfgang Vogel; Michael Trauner; Markus Peck-Radosavljevic
Journal:  Hepatology       Date:  2013-01-18       Impact factor: 17.425

Review 4.  Inflammation- and stress-related signaling pathways in hepatocarcinogenesis.

Authors:  Hayato Nakagawa; Shin Maeda
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

5.  A prospective study of serum C-reactive protein and colorectal cancer risk in men.

Authors:  Marc J Gunter; Rachael Stolzenberg-Solomon; Amanda J Cross; Michael F Leitzmann; Stephanie Weinstein; Richard J Wood; Jarmo Virtamo; Philip R Taylor; Demetrius Albanes; Rashmi Sinha
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

6.  Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma.

Authors:  Hiroaki Shiba; Kenei Furukawa; Yuki Fujiwara; Yasuro Futagawa; Koichiro Haruki; Shigeki Wakiyama; Yuichi Ishida; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  Anticancer Res       Date:  2013-02       Impact factor: 2.480

7.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

8.  Serum C-reactive protein levels predict survival in hepatocellular carcinoma.

Authors:  Sakae Nagaoka; Takafumi Yoshida; Junji Akiyoshi; Jun Akiba; Takuji Torimura; Hisashi Adachi; Junichi Kurogi; Nobuyoshi Tajiri; Kinya Inoue; Takashi Niizeki; Hironori Koga; Tsutomu Imaizumi; Masamichi Kojiro; Michio Sata
Journal:  Liver Int       Date:  2007-10       Impact factor: 5.828

Review 9.  Chronic inflammation and cytokines in the tumor microenvironment.

Authors:  Glauben Landskron; Marjorie De la Fuente; Peti Thuwajit; Chanitra Thuwajit; Marcela A Hermoso
Journal:  J Immunol Res       Date:  2014-05-13       Impact factor: 4.818

10.  Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Zhiyun Zheng; Lin Zhou; Sheng Gao; Zhe Yang; Jia Yao; Shusen Zheng
Journal:  Int J Med Sci       Date:  2013-04-01       Impact factor: 3.738

View more
  3 in total

1.  Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.

Authors:  Hikmet Akkiz; Brian I Carr; Harika G Bag; Ümit Karaoğullarından; Kendal Yalçın; Nazim Ekin; Ayşegül Özakyol; Engin Altıntaş; Hatice Y Balaban; Halis Şimşek; Ahmet Uyanıkoğlu; Ayhan Balkan; Sedef Kuran; Oğuz Üsküdar; Yakup Ülger; Burak Güney; Anil Delik
Journal:  Int J Clin Pract       Date:  2020-12-12       Impact factor: 2.503

Review 2.  Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Stijn Van Hees; Peter Michielsen; Thomas Vanwolleghem
Journal:  World J Gastroenterol       Date:  2016-10-07       Impact factor: 5.742

3.  TFCP2 Genetic Polymorphism Is Associated with Predisposition to and Transplant Prognosis of Hepatocellular Carcinoma.

Authors:  Zhikun Liu; Feng Gao; Zhou Shao; Haiyang Xie; Lin Zhou; Xiao Xu; Shusen Zheng
Journal:  Gastroenterol Res Pract       Date:  2017-02-27       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.